4-甲基-1氢-吲哚-2-甲酸乙酯 | 16732-80-2

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 4-甲基-1氢-吲哚-2-甲酸乙酯
• 英文名称: ethyl 4-methyl-1H-indole-2-carboxylate
• 英文别名: 4-methyl-1H-indole-2-carboxylic acid ethyl ester
• CAS: 16732-80-2
• 化学式: C₁₂H₁₃NO₂
• 分子量: 203.241
• InChiKey: ZUJVXCIAKURESZ-UHFFFAOYSA-N

物化性质

• 熔点：
  140-141 °C
• 沸点：
  355.6±22.0 °C(Predicted)
• 密度：
  1.177±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: ethyl 4-methyl-1H-indole-2-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: ethyl 4-methyl-1H-indole-2-carboxylate
CAS number: 16732-80-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H13NO2
Molecular weight: 203.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基-1氢-吲哚-2-甲酸乙酯 在 sodium hydroxide 、 sodium hydride 作用下， 生成 4-甲基吲哚-2-羧酸
  参考文献：
  名称：

  Indole derivatives as inhibitors or factor Xa

  摘要：

  本发明涉及抑制血液凝块蛋白，更具体地说是与式(I)中的吲哚衍生物有关，其中R1a、R1b、R1c、R1d、R2、R3、R4和A的定义如索赔中所示。式(I)化合物是血液凝块酶因子Xa的抑制剂。本发明还涉及制备式(I)化合物的方法，抑制因子Xa活性和血液凝块形成的方法，以及利用式(I)化合物在治疗和预防可通过抑制因子Xa活性治愈或预防的疾病中的用途，如血栓栓塞性疾病，并且利用式(I)化合物制备用于治疗此类疾病的药物。本发明还涉及含有式(I)化合物的组合物，与惰性载体混合或以其他方式与之结合，特别是含有式(I)化合物的药物组合物，连同药用载体物质和/或辅助物质。

  公开号：

  US06337344B1
• 作为产物：
  描述：

  4-methylindole-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以94%的产率得到4-甲基-1氢-吲哚-2-甲酸乙酯
  参考文献：
  名称：

  [DE] HETEROCYCLYL-SUBSTITUIERTE DIHYDROCHINAZOLINE UND IHRE VERWENDUNG ALS ANTIVIRALE MITTEL
  [EN] HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT
  [FR] DIHYDROQUINAZOLINES SUBSTITUEES PAR HETEROCYCLYLE ET LEUR UTILISATION COMME ANTIVIRAUX

  摘要：

  这项发明涉及式(I)的杂环取代二氢喹啉，以及其制备方法和用途，用于制备用于治疗和/或预防疾病的药物，特别是用作抗病毒药物，特别是对抗巨细胞病毒。

  公开号：

  WO2004099212A1

文献信息

• Regio‐ and Enantioselective (3+3) Cycloaddition of Nitrones with 2‐Indolylmethanols Enabled by Cooperative Organocatalysis
  作者：Tian‐Zhen Li、Si‐Jia Liu、Yu‐Wen Sun、Shuang Deng、Wei Tan、Yinchun Jiao、Yu‐Chen Zhang、Feng Shi

  DOI：10.1002/anie.202011267

  日期：2021.2

  regiospecificity. This approach enabled not only the first organocatalytic asymmetric (3+3) cycloaddition of nitrones but also the first C3‐nucleophilic asymmetric (3+3) cycloaddition of 2‐indolylmethanols. More importantly, theoretical calculations elucidated the role of the cocatalyst HFIP in helping CPA control the reactivity and enantioselectivity of the reaction, demonstrating a new mode of cooperative catalysis

  硝酮与2-吲哚基甲醇的区域和对映选择性（3 + 3）环加成反应是通过六氟异丙醇（HFIP）和手性磷酸（CPA）的协同催化完成的。使用这种方法，以高收率（高达98％），优异的对映选择性（高达96％ee）和排他的区域特异性合成了一系列吲哚稠合的六元杂环。这种方法不仅可以实现硝酮的首次有机催化不对称（3 + 3）环加成反应，而且还可以实现2-吲哚基甲醇的首次C3-亲核不对称（3 + 3）环加成反应。更重要的是，理论计算阐明了助催化剂HFIP在帮助CPA控制反应的反应性和对映选择性方面的作用，证明了一种新型的协同催化方式。
• [DE] HETEROCYCLYL-SUBSTITUIERTE DIHYDROCHINAZOLINE UND IHRE VERWENDUNG ALS ANTIVIRALE MITTEL<br/>[EN] HETEROCYCLYL-SUBSTITUTED DIHYDROQUINAZOLINES AND USE THEREOF AS AN ANTIVIRAL AGENT<br/>[FR] DIHYDROQUINAZOLINES SUBSTITUEES PAR HETEROCYCLYLE ET LEUR UTILISATION COMME ANTIVIRAUX
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004099212A1

  公开（公告）日：2004-11-18

  Die Erfindung betrifft Heterocyclyl-substituierte Dihydrochinazoline der Formel (I) und Verfahren zu ihrer Herstellung sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere zur Verwendung als antivirale Mittel, insbesondere gegen Cytomegaloviren.

  这项发明涉及式(I)的杂环取代二氢喹啉，以及其制备方法和用途，用于制备用于治疗和/或预防疾病的药物，特别是用作抗病毒药物，特别是对抗巨细胞病毒。
• Tripeptidyl peptidase inhibitors
  申请人：Institut National de la Sante et de la Recherche Medicale (INSERM)

  公开号：US06335360B1

  公开（公告）日：2002-01-01

  The invention is relative to a compound of formula (I) and its use as an inhibitor of the CCK-inactivating peptidase tripeptidyl peptidase (TPP II). The invention concerns in particular the treatment of eating disorder, obesity, psychotic syndrome and associated psychiatric disorders. It concerns also the cosmetic use of a compound (I) in particular to aid slimming.

  这项发明涉及一种化合物的公式(I)，以及其作为CCK失活肽酶三肽肽酶(TPP II)的抑制剂的用途。该发明特别涉及治疗进食障碍、肥胖、精神症候群及相关精神障碍。还涉及一种化合物(I)的化妆用途，特别是用于辅助减肥。
• Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040043995A1

  公开（公告）日：2004-03-04

  The invention relates to a compound of formula 1 in which R 1 , X 1 , X 2 , X 3 , X 4 , R 4 , Y 1 , Y 2 and Y 3 are as defined in claim 1. These compounds are CCK-receptor agonists.

  这项发明涉及一种具有以下结构的化合物，其中R1、X1、X2、X3、X4、R4、Y1、Y2和Y3如权利要求1中所定义。这些化合物是CCK受体激动剂。
• INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE
  申请人：Bolin David Robert

  公开号：US20100145047A1

  公开（公告）日：2010-06-10

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.

  本文提供的是式(I)的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如肥胖、2型糖尿病和代谢综合征等疾病是有用的。